Daily Stock Analysis, CORN, CORIUM INTERNATIONAL INC, priceseries

CORIUM INTERNATIONAL INC. Daily Stock Analysis
Stock Information
Open
19.58
Close
19.81
High
19.85
Low
19.53
Previous Close
19.63
Daily Price Gain
0.18
YTD High
22.98
YTD High Date
May 7, 2021
YTD Low
15.46
YTD Low Date
Jan 4, 2021
YTD Price Change
4.22
YTD Gain
27.07%
52 Week High
22.98
52 Week High Date
May 7, 2021
52 Week Low
12.59
52 Week Low Date
Sep 28, 2020
52 Week Price Change
7.09
52 Week Gain
55.74%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 16. 2019
15.44
Jun 5. 2019
16.43
13 Trading Days
6.41%
Link
LONG
Aug 20. 2020
12.15
Sep 22. 2020
12.93
22 Trading Days
6.38%
Link
LONG
Dec 17. 2020
14.28
Jan 22. 2021
16.29
23 Trading Days
14.07%
Link
LONG
Apr 13. 2021
18.01
May 12. 2021
21.71
21 Trading Days
20.55%
Link
Company Information
Stock Symbol
CORN
Exchange
NASDAQ
Company URL
http://www.coriumgroup.com
Company Phone
650-298-8012
CEO
Peter D. Staple
Headquarters
California
Business Address
235 CONSTITUTION DRIVE, MENLO PARK, CA 94025
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001594337
About

Corium International, Inc. is a commercial stage biopharmaceutical company, which develops, manufactures and commercializes of specialty pharmaceutical products. The company development platforms enable transdermal delivery of large molecules or biologics, including vaccines, peptides and proteins, as well as small molecules that are otherwise difficult to deliver in a transdermal dosage form. Corium International was founded by Gary W. Cleary and Adrian L. Faasse, Jr. in 1995 and is headquartered in Menlo Park, CA.

Description

Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, that has completed Phase III clinical trial to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trial for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trial for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Ropinirole TDS that is in preclinical stage for the treatment of Parkinson's disease; MicroCor Zolmitriptan that is in preclinical stage for treatment of migraine; and generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements primarily with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Endo Pharmaceuticals, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.